Herantis Pharma Plc.

Other

Licentia, Ltd.

Maria Lindahl

Mart Saarma

Raimo Tuominen

Merja Voutilainen

Johan Peränen

Mikko Airavaara

Veli-Matti Leppänen

Jaan-Olle Andressoo

Petro Suvanto

Päivi Lindholm

Hannu Sariola

Päivi Pulkkila

Kirsi Sainio

Urmas Arumae

Jari Rossi

Tönis Timmusk

Dimitri Poteriaev

Matti Airaksinen

Johan Peranen

Veli-Matti Leppanen

The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.

Neurotrophic factor MANF and uses thereof

The present invention discloses purified and isolated nucleic acid sequences encoding polypeptides having a structure substantially similar to that of splicing forms of mammalian GFR&#x3b1;4 comprising the amino acid sequence (SEQ ID NO:1:)-(SEQ ID NO:6:). The preferred sequences comprise cDNAs having the sequence (SEQ ID NO:7:)-(SEQ ID NO:13:). The present invention is also related to purified and isolated polypeptides comprising the amino acid sequence and or substantially similar splicing forms of mammalian GFR&#xe0;4. Furthermore, the invention is related to substances capable of specifically recognizing said polypeptides and including both antibodies and receptors. The active compounds of the present invention including cDNAS, polypeptides, binding substances, and antibodies. The invention is useful not only for producing cell-lines and/or transgenic non-human animal but also for diagnosing and treating neuronal disorders or endocrine tumors as well as other related diseases by enabling measurements of GFR&#x3b1;4-mediated signalling in endocrine cells and neurons.

Compounds related to or derived from GFR &#x3b1;4 and their use

The effect of GDNF on kidney morphogenesis is disclosed. Methods for stimulating budding and branching of the ureteric epithelium, for stimulating axonal outgrowth, for maintaining ureteric epithelial cells in culture, for preventing apoptosis of ureteric epithelial cells, and for treating diseases using GDNF are also disclosed.

Glial cell line-derived neurotrophic factor regulation of ureteric

Growing community of inventors

Espoo, Finland

Maria Lindahl